Myocardial injury induces significant changes in ventricular structure and function at both the cellular and anatomic level, leading to ventricular remodeling and subsequent heart failure. Unloading left ventricular pressure has been studied in both the short-term and long-term settings, as a means of preventing or reversing cardiac remodeling. In acute myocardial infarction, cardiac unloading is used to reduce oxygen demand and limit infarct size. Research has demonstrated the benefits of short-term unloading with mechanical circulatory support devices before reperfusion in the context of acute myocardial infarction with cardiogenic shock, and a confirmatory trial is ongoing. In chronic heart failure, ventricular unloading using mechanical circulatory support can reverse many of the cellular and anatomic changes that accompany ventricular remodeling. Ongoing research is evaluating the ability of left ventricular assist devices to promote myocardial recovery and remission from clinical heart failure. States annually. Over the past 3 decades, early revascularization and AMI management have had a significant impact on early mortality, and 30-day survival for ST-segment elevation myocardial infarction is now 95%. However, 1 in 4 patients surviving a first AMI will develop heart failure (HF) within 1 year, and 75% will develop HF within 5 years from the index event (1). As more people survive the initial AMI, an increasingly heavy burden is placed on our health care system in the form of new HF patients.
A cute myocardial infarction (AMI) remains a leading cause of morbidity and mortality, with >650,000 cases reported in the United States annually. Over the past 3 decades, early revascularization and AMI management have had a significant impact on early mortality, and 30-day survival for ST-segment elevation myocardial infarction is now 95%. However, 1 in 4 patients surviving a first AMI will develop heart failure (HF) within 1 year, and 75% will develop HF within 5 years from the index event (1) . As more people survive the initial AMI, an increasingly heavy burden is placed on our health care system in the form of new HF patients.
Additional therapeutic approaches focusing on HF prevention should be developed. 
VENTRICULAR REMODELING
Acute or chronic myocardial injury precipitates metabolic derangement, followed by myocyte death. The remaining viable myocardium responds to cell loss through myocyte hypertrophy and development of fibrosis in the interstitial space (2, 3) . A reduction in contractile force activates neurohormonal compensatory mechanisms aimed at maintaining systemic perfusion such as the sympathetic nervous and reninangiotensin systems. Over time, the LV undergoes structural changes including an increase in ventricular volume, rightward shift of the end-diastolic pressure-volume relationship (EDPVR) and development of a more spherical shape (4) (5) (6) . These anatomic changes are accompanied by alterations in gene expression, metabolic substrate preference and utilization, and the composition of the extracellular matrix (7) (8) (9) . Together, these structural, biochemical, and molecular changes are termed ventricular remodeling.
ACUTE HEART FAILURE FOLLOWING AMI
Infarct size correlates with mortality and development of HF (10) . The larger the infarct, the higher the burden on remaining viable myocardium and the greater the adaptive cardiomyocyte hypertrophy.
Myocardial infarction initiates the process of ventricular remodeling as described in the preceding text. Accordingly, limiting myocardial injury is the primary target of clinical investigations aimed at preventing HF after an AMI. Two primary approaches have been pursued. The first is to minimize the overall ischemic time experienced by the myocardium. The adage "time is muscle" suggests that the faster an occluded coronary artery can be reperfused and myocardial oxygen supply restored, the smaller the infarct size. This has led to adoption of a benchmark door-to-balloon time, the time from arrival to a medical facility to primary reperfusion, of 90 min or less. However, recent reports demonstrate no effect on mortality or post-AMI HF incidence with additional reduction in the door-toballoon time below 90 min (11). The second approach to limit infarct size in AMI has been to employ interventions and pharmacotherapy to reduce reperfusion injury. These methods have been reviewed extensively and are founded on solid preclinical data, but none have successfully translated into routine clinical practice (12) .
A key pathophysiological feature that determines the extent of necrosis during AMI is the balance between the residual supply of oxygen to the myocardium at risk and myocardial metabolic demands.
Although the current paradigm-early reperfusion therapy-focuses on restoring oxygen supply to the myocardium at risk, strategies to reduce myocardial oxygen demand to achieve a more favorable supplydemand ratio as a means of limiting infarct size have not been clinically tested. Extensive preclinical and some clinical evidence suggest that immediately reducing the mechanical workload (unloading) of the heart before reperfusion leads to a smaller infarct size. Short-term cardiac unloading reduces oxygen demand and preconditions myocardium at risk to oppose reperfusion injury, and may limit irreversible necrosis, allowing the heart to more fully recover once coronary flow is restored. Here, we provide an overview of the hemodynamic principles and physiological mechanisms underlying short-and long-term unloading, and discuss emerging preclinical data supporting translation of this approach to limiting infarct size and preventing the development of HF. Heart rate is a critical determinant of oxygen consumption because both calcium cycling and mechanical work occur with each beat. Thus, the oxygen required to fuel these processes increases linearly with increases of heart rate. Accordingly, myocardial oxygen demand can be decreased by reducing heart rate, contractility, and/or total mechanical work. Each component should be considered when attempting to achieve maximal cardiac unloading. tantly, there is an increase in total cardiac output (i.e., the sum of native heart and LVAD flow), thereby shifting oxygen demand/supply balance within the heart, minimizing demand while maximizing supply.
SHORT-TERM CARDIAC UNLOADING

MOLECULAR BIOLOGY OF UNLOADING IN THE SETTING OF ISCHEMIA-REPERFUSION INJURY
In 1985, Eugene Braunwald and Robert Kloner (17) described myocardial reperfusion in AMI as a "double-edged sword" due to the fact that reperfusion of ischemic myocardium also promotes cardiomyocyte death and microvascular damage through a process referred to as myocardial ischemia-reperfusion injury. Since then, multiple studies have defined several key mechanisms that drive myocardial
damage during ischemia and reperfusion (18) (19) (20) (21) (22) . In parallel to the growing body of published reports exploring biological mechanisms of cardioprotection, 
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Uriel et al. This study highlights the importance of actively attempting to achieve myocardial recovery through aggressive medical management and systematically looking for evidence of recovery during LVAD support. Importantly, the LV should be evaluated in a reloaded state (i.e., during minimal degrees of LVAD support) to fully assess function, although it remains debatable whether it is important to slowly recondition the heart through gradually increased loading over time (77) .
CONCLUSIONS
Cardiac unloading reduces mechanical power expenditure of the LV, minimizing MVO2 and reducing ventricular remodeling (Central Illustration).
Unloading can be achieved both in AMI and chronic HF. There is a significant body of evidence demonstrating that initiation of cardiac unloading leads to anatomic, cellular, molecular, and genetic changes in both the short-and long-term setting.
Current studies are focusing on the clinical applications of early unloading in the setting of myocardial infarction as a tool to reduce infarct size (DTU trial), and late unloading to achieve partial or complete myocardial recovery in chronic HF to test the degree to which partial or complete myocardial recovery can be achieved in patients with chronic HF (RESTAGE-HF study). 
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